Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areassort descending Investigator Organization Phase Trial Status Targeted Enrollment Detail
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
  • Anemia
  • Bone Marrow Transplant and Viral Infection
 Alice Bertaina Stanford University Phase 1/2 Launching N/A
  • Anemia
 Matthew Porteus Stanford University Phase 1/2 Launching N/A
Kristen Johnson Calibr Phase 1 Completed 60
  • B cell cancers
 Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Recruiting 148
Thomas Kipps University of California, San Diego Phase 1/2 Active, not recruiting 102
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
 Matthew Porteus Stanford University Phase 1 Recruiting 22
David Miklos Stanford University Phase 1 Recruiting 60
  • Beta Thalassemia
 Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
  • Bladder or Urinary Tract Disorder
 James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Irving Weissman Stanford University Phase 1 Completed 88
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 234
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Christine Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Crystal Mackall Stanford University Phase 1 Recruiting 54
Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
  • Corneal Damage
 Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
  • COVID-19
 Michael Matthay University of California, San Francisco Phase 2 Active, not recruiting 120
William van der Touw Celularity Inc. Phase 1/2 Active, not recruiting 86
Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
  • Epilepsy
 Cory Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
Linda Marban Capricor, Inc Phase 2 Completed 25
Rachel Smith Capricor, Inc Phase 2 Closed 156
Joseph Wu Stanford University Phase 1 Recruiting 18
Mehrdad Abedi University of California, Davis Phase 1/2 Active, not recruiting 11
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
William Kennedy Excision BioTherapeutics Phase 1 Recruiting 9
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
  • Immune Disease
  • Pediatrics
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 16
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Suspended 28
  • Immune Disease
  • Leukocyte Adhesion Deficiency
 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
  • IPEX Syndrome
 Rosa Bacchetta Stanford University Phase 1 Recruiting 36
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 240
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
Everett Meyer Stanford University Phase 1 Recruiting 22
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Leukemia, Acute Myeloid (AML)
 Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 122
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Active, not recruiting 258
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
  • Multiple Myeloma
 Rajesh Belani Poseida Therapeutics, Inc. Phase 1 Closed 105
  • Muscle Injury
 Peter Belafsky University of California, Davis Phase 1/2 Recruiting 62
Thomas Chalberg Genascence Corporation Phase 1 Launching N/A
Nancy Lane University of California, Davis Phase 1/2 Completed 58
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
  • Pulmonary Hypertension
  • Vascular Disease
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 26
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Henry Klassen jCyte, Inc Phase 2 Completed 84
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Henry Klassen jCyte, Inc Phase 2 Completed 84
  • Sarcoma
 Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
David Williams Boston Children's Hospital Phase 2 Active, not recruiting 10
Mark Walters University of California, San Francisco Phase 1 Launching N/A
De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
Dennis Slamon University of California, Los Angeles Phase 1 Completed 46
Pamela Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 24
  • Spina Bifida
 Diana Farmer University of California, Davis Phase 1 Recruiting 55
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Francois Binette Lineage Cell Therapeutics, Inc. Phase 1/2 Completed 25
Gary Steinberg Stanford University Phase 1 Recruiting 30
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Manasi Jaiman ViaCyte, Inc. Phase 1/2 Active, not recruiting 49
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Icon for XLSX export